InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,306.00
(
0.04%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
73.61
(
-0.38%
)
Bitcoin
63,163.92
(
-0.72%
)
Post# of 253196
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DewDiligence post# 210691

Friday, 04/28/2017 4:32:11 PM

Friday, April 28, 2017 4:32:11 PM

Post# of 253196
>>Humira pricing

I am reliably informed that a CEO of one of the competitors in the same space (RA biologics) claimed he could set the price of his rival drug at zero and it still wouldn't get on some formularies.

I can't say I fully understand the dynamics, but it has something to do with rebates and Humira having a broader label. So I could speculate that the rebates depend on hitting a minimum sales level and if you removed RA sales from Humira there would be a huge hit on the other indications.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up